Listerine meeting postponed
This article was originally published in The Tan Sheet
"Feedback" meeting on Pfizer's proposed changes to the OTC anticaries final monograph, originally slated for June 18, will be rescheduled within a month to give Division of OTC Drug Products more time to review relevant material, FDA says June 14. Meeting is part of Pfizer's efforts to amend monograph to allow for a mouthrinse combining essential oils, sodium fluoride (1"The Tan Sheet" June 10, 2002, p. 3)...
You may also be interested in...
Pfizer Consumer Healthcare plans to conduct a six-month clinical study involving at least 300 subjects to determine whether adding .02% sodium fluoride to the company's Listerine mouthrinse affects the antiplaque/ antigingivitis effectiveness of the product
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from the year so far.
US Regulatory Roundup, February 2021: QA/RA Predictions, FDA Warning Letter Stats, PMA Case Study, And More
Quality and regulatory predictions for 2021, a count of 2020 US FDA enforcement missives, a premarket approval case study for a novel prosthetic, and more topped our list of most-read Medtech Insight articles in February.